Skip to Content
Merck

Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration.

Antimicrobial agents and chemotherapy (2014-05-14)
Roger Badia, Eduardo Pauls, Eva Riveira-Munoz, Bonaventura Clotet, José A Esté, Ester Ballana
ABSTRACT

Genome editing using zinc finger nucleases (ZFNs) has been successfully applied to disrupt CCR5 or CXCR4 host factors and inhibit viral entry and infection. Gene therapy using ZFNs to modify the PSIP1 gene, which encodes the lens epithelium-derived growth factor (LEDGF) protein, might restrain an early step of the viral replication cycle at the integration level. ZFNs targeting the PSIP1 gene (ZFNLEDGF) were designed to specifically recognize the sequence after the integrase binding domain (IBD) of the LEDGF/p75 protein. ZFNLEDGF successfully recognized the target region of the PSIP1 gene in TZM-bl cells by heteroduplex formation and DNA sequence analysis. Gene editing induced a frameshift of the coding region and resulted in the abolishment of LEDGF expression at the mRNA and protein levels. Functional assays revealed that infection with the HIV-1 R5 BaL or X4 NL4-3 viral strains was impaired in LEDGF/p75 knockout cells regardless of entry tropism due to a blockade in HIV-1 proviral integration into the host genome. However, residual infection was detected in the LEDGF knockout cells. Indeed, LEDGF knockout restriction was overcome at a high multiplicity of infection, suggesting alternative mechanisms for HIV-1 genome integration rather than through LEDGF/p75. However, the observed residual integration was sensitive to the integrase inhibitor raltegravir. These results demonstrate that the described ZFNLEDGF effectively targets the PSIP1 gene, which is involved in the early steps of the viral replication cycle; thus, ZFNLEDGF may become a potential antiviral agent for restricting HIV-1 integration. Moreover, LEDGF knockout cells represent a potent tool for elucidating the role of HIV integration cofactors in virus replication.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3′-Azido-3′-deoxythymidine, ≥98% (HPLC)
USP
Zidovudine, United States Pharmacopeia (USP) Reference Standard
Zidovudine, European Pharmacopoeia (EP) Reference Standard
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material